Table 1.
Clinical and pathological characteristics of patients with OSCC with high- or low-risk lncRNA signature in the three datasets
| Training set (n=60) | Test set (n=59) | Independent set (n=60) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics | High-risk group (n=33) | Low-risk group (n=27) | p Value | High-risk group (n=25) | Low-risk group (n=34) | p Value | High-risk group (n=37) | Low-risk group (n=23) | p Value |
| Age, median (IQR) | 59.0 (11.0) | 55.0 (17.5) | 0.7976* | 62.0 (12.0) | 59.0 (9.5) | 0.3834* | 62.0 (13.0) | 58.0 (11.0) | 0.8231 |
| Gender, male | 26 (78.8) | 23 (85.2) | 0.7391 | 21 (84.0) | 28 (82.4) | 1.0000 | 28 (75.7) | 20 (87.0) | 0.3404 |
| Tobacco use, yes | 19 (57.6) | 20 (74.1) | 0.1825 | 18 (72.0) | 23 (67.6) | 0.7197 | 18 (48.6) | 16 (69.6) | 0.1119 |
| Alcohol use, yes | 20 (60.6) | 16 (59.3) | 0.9156 | 16 (64.0) | 22 (64.7) | 0.9554 | 18 (48.6) | 14 (60.9) | 0.3562 |
| Tumour location | 0.2460 | 0.5411 | 0.3780 | ||||||
| Upper | 7 (21.2) | 2 (7.4) | 1 (4.0) | 4 (11.8) | 5 (13.5) | 1 (4.3) | |||
| Middle | 15 (45.5) | 17 (63.0) | 17 (68.0) | 20 (58.8) | 18 (48.6) | 10 (43.5) | |||
| Lower | 11 (33.3) | 8 (29.6) | 7 (28.0) | 10 (29.4) | 14 (37.8) | 12 (52.2) | |||
| Tumour grade | 0.5977 | 0.3126 | 0.4270 | ||||||
| Well differntiated | 8 (24.2) | 6 (22.2) | 4 (16.0) | 5 (14.7) | 4 (10.8) | 5 (21.7) | |||
| Moderately differentiated | 17 (51.5) | 17 (63.0) | 10 (40.0) | 20 (58.8) | 21 (56.8) | 13 (56.5) | |||
| Poorly differentiated | 8 (24.2) | 4 (14.8) | 11 (44.4) | 9 (26.5) | 12 (32.4) | 5 (21.7) | |||
| T stage | 0.2524 | 0.1632 | 0.2271 | ||||||
| T1 | 1 (3.0) | 2 (7.4) | 1 (4.0) | 4 (11.8) | 1 (2.7) | 3 (13.0) | |||
| T2 | 3 (9.1) | 2 (7.4) | 4 (16.0) | 11 (32.4) | 5 (13.5) | 2 (8.7) | |||
| T3 | 17 (51.5) | 19 (70.4) | 15 (60.0) | 11 (32.4) | 31 (83.8) | 17 (73.9) | |||
| T4 | 12 (36.4) | 4 (14.8) | 5 (20.0) | 8 (23.5) | 0 | 1 (6.3) | |||
| N stage | 0.1350 | 0.0290 | 0.7255 | ||||||
| N0 | 11 (33.3) | 16 (59.3) | 6 (24.0) | 21 (61.8) | 16 (43.2) | 13 (56.5) | |||
| N1 | 18 (54.5) | 8 (29.6) | 9 (36.0) | 7 (20.6) | 14 (37.8) | 6 (26.1) | |||
| N2 | 1 (3.0) | 2 (7.4) | 7 (28.0) | 3 (8.8) | 6 (16.2) | 3 (13.0) | |||
| N3 | 3 (9.1) | 1 (3.7) | 3 (12.0) | 3 (8.8) | 1 (2.7) | 1 (4.3) | |||
| TNM stage | 0.1106 | 0.0378 | 0.5552 | ||||||
| I | 0 | 2 (7.4) | 0 | 4 (11.8) | 2 (5.4) | 2 (8.7) | |||
| II | 10 (30.3) | 12 (44.4) | 8 (32.0) | 17 (50.0) | 17 (45.9) | 13 (56.5) | |||
| III | 23 (69.7) | 13 (48.1) | 17 (68.0) | 13 (38.2) | 18 (48.6) | 8 (34.8) | |||
| Tumour clearance | N/A | N/A | N/A | ||||||
| R0 | 33 (100) | 27 (100) | 25 (100) | 34 (100) | 37 (100) | 23 (100) | |||
| R1/R2 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Postoperative complication | |||||||||
| Pneumonia | 1 (3.0) | 1 (3.7) | 1.0000 | 6 (24.0) | 4 (11.8) | 0.2970 | 2 (5.4) | 1 (4.3) | 1.0000 |
| Anastomotic leak | 3 (9.1) | 1 (3.7) | 0.6199 | 3 (12.0) | 4 (11.8) | 1.0000 | 1 (2.7) | 0 | 1.0000 |
| Arrhythmia | 11 (33.3) | 5 (18.5) | 0.2481 | 9 (36.0) | 2 (5.9) | 0.0055 | 10 (27.0) | 6 (26.1) | 1.0000 |
| Adjuvant therapy | 0.6209 | 0.2585 | 0.5196 | ||||||
| Yes | 20 (60.6) | 13 (48.1) | 16 (64.0) | 20 (58.8) | 23 (62.2) | 12 (52.2) | |||
| No | 8 (24.2) | 9 (33.3) | 1 (4.0) | 6 (17.6) | 11 (29.7) | 10 (43.5) | |||
| Unknown | 5 (15.2) | 5 (18.5) | 16 (27.1) | 8 (35.5) | 3 (8.1) | 1 (4.3) | |||
| Median survival (months) | 19.2 | >60 | <0.0001† | 21.5 | >60 | 0.0030† | 25.8 | >48 | 0.0187† |
Data are shown as n (%). p Values are calculated by χ2 test or Fisher's exact test, unless otherwise stated.
*Student's t test.
†Log-rank test. N/A: p values are not calculated because all patients received R0 resection.
OSCC, oesophageal squamous cell carcinoma; TNM, tumour node metastasis.